Intellia Therapeutics (NASDAQ:NTLA) Trading Up 8.8% – Still a Buy?

Intellia Therapeutics, Inc. (NASDAQ:NTLA) shares were up 8.8% on Thursday . The company traded as high as $13.89 and last traded at $14.1610. Approximately 561,798 shares changed hands during mid-day trading, a decline of 90% from the average daily volume of 5,390,905 shares. The stock had previously closed at $13.02.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on NTLA shares. Weiss Ratings restated a “sell (d-)” rating on shares of Intellia Therapeutics in a research note on Tuesday, April 21st. Truist Financial upgraded Intellia Therapeutics to a “strong-buy” rating in a research note on Wednesday, March 25th. Citigroup restated an “outperform” rating on shares of Intellia Therapeutics in a research note on Tuesday, April 28th. restated a “buy” rating on shares of Intellia Therapeutics in a research note on Tuesday, March 3rd. Finally, Robert W. Baird increased their price target on Intellia Therapeutics from $7.00 to $13.00 and gave the company a “neutral” rating in a research note on Monday, April 27th. One investment analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, ten have assigned a Hold rating and three have given a Sell rating to the company’s stock. According to MarketBeat.com, Intellia Therapeutics presently has an average rating of “Hold” and a consensus price target of $20.25.

Intellia Therapeutics Price Performance

The company has a market cap of $1.89 billion, a P/E ratio of -3.82 and a beta of 1.92. The stock has a 50-day moving average of $13.61 and a 200 day moving average of $12.14.

Intellia Therapeutics (NASDAQ:NTLA) last issued its quarterly earnings results on Monday, May 11th. The company reported ($0.81) EPS for the quarter, topping analysts’ consensus estimates of ($0.92) by $0.11. Intellia Therapeutics had a negative return on equity of 57.47% and a negative net margin of 597.04%.The company had revenue of $15.05 million for the quarter, compared to analysts’ expectations of $13.81 million. During the same quarter last year, the business earned ($1.10) earnings per share. Sell-side analysts predict that Intellia Therapeutics, Inc. will post -3.23 EPS for the current year.

Institutional Trading of Intellia Therapeutics

Several large investors have recently bought and sold shares of the business. Oppenheimer & Co. Inc. boosted its stake in Intellia Therapeutics by 0.8% in the fourth quarter. Oppenheimer & Co. Inc. now owns 105,165 shares of the company’s stock valued at $945,000 after buying an additional 808 shares in the last quarter. Comerica Bank boosted its stake in Intellia Therapeutics by 45.8% in the fourth quarter. Comerica Bank now owns 2,869 shares of the company’s stock valued at $26,000 after buying an additional 901 shares in the last quarter. Federated Hermes Inc. boosted its stake in Intellia Therapeutics by 39.7% in the third quarter. Federated Hermes Inc. now owns 3,263 shares of the company’s stock valued at $56,000 after buying an additional 927 shares in the last quarter. PNC Financial Services Group Inc. boosted its stake in Intellia Therapeutics by 36.4% in the first quarter. PNC Financial Services Group Inc. now owns 3,552 shares of the company’s stock valued at $46,000 after buying an additional 948 shares in the last quarter. Finally, Wealthfront Advisers LLC boosted its stake in Intellia Therapeutics by 7.6% in the first quarter. Wealthfront Advisers LLC now owns 14,450 shares of the company’s stock valued at $185,000 after buying an additional 1,018 shares in the last quarter. 88.77% of the stock is owned by institutional investors and hedge funds.

About Intellia Therapeutics

Intellia Therapeutics, Inc (NASDAQ: NTLA) is a clinical‐stage biotechnology company focused on developing potentially curative genome editing therapies using the CRISPR/Cas9 platform. The company’s research spans both in vivo and ex vivo applications of CRISPR/Cas9, aiming to correct or disable disease‐causing genes with a single administration. Intellia’s lead in vivo program targets transthyretin amyloidosis (ATTR) by delivering CRISPR/Cas9 machinery directly to the liver, while additional preclinical efforts pursue treatments for hemophilia A, hereditary angioedema and other genetic disorders.

Beyond its in vivo pipeline, Intellia collaborates with strategic partners to extend the impact of its genome editing approach.